234 related items for PubMed ID: 21922213
1. Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome.
Sinha A, Bagga A, Gulati A, Hari P.
Pediatr Nephrol; 2012 Feb; 27(2):235-41. PubMed ID: 21922213
[Abstract] [Full Text] [Related]
2. Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children.
Basu B, Babu BG, Mahapatra TK.
Clin Exp Nephrol; 2017 Feb; 21(1):143-151. PubMed ID: 27108294
[Abstract] [Full Text] [Related]
3. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.
Bagga A, Hari P, Moudgil A, Jordan SC.
Am J Kidney Dis; 2003 Dec; 42(6):1114-20. PubMed ID: 14655181
[Abstract] [Full Text] [Related]
4. Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.
DaSilva I, Huerta A, Quintana L, Redondo B, Iglesias E, Draibe J, Praga M, Ballarín J, Díaz-Encarnación M, Spanish Group for the Study of Glomerular Diseases (GLOSEN).
BioDrugs; 2017 Jun; 31(3):239-249. PubMed ID: 28534103
[Abstract] [Full Text] [Related]
5. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group.
Lancet; 2014 Oct 04; 384(9950):1273-81. PubMed ID: 24965823
[Abstract] [Full Text] [Related]
6. Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial.
Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, Schaefer F.
JAMA Pediatr; 2018 Aug 01; 172(8):757-764. PubMed ID: 29913001
[Abstract] [Full Text] [Related]
7. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
Sinha A, Bhatia D, Gulati A, Rawat M, Dinda AK, Hari P, Bagga A.
Nephrol Dial Transplant; 2015 Jan 01; 30(1):96-106. PubMed ID: 25121488
[Abstract] [Full Text] [Related]
8. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, Udagawa T, Iijima K.
Pediatr Nephrol; 2011 Oct 01; 26(10):1823-8. PubMed ID: 21556716
[Abstract] [Full Text] [Related]
9. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
Webb NJ, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Wheatley K, Ives NJ.
Health Technol Assess; 2019 May 01; 23(26):1-108. PubMed ID: 31156083
[Abstract] [Full Text] [Related]
10. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.
Sinha A, Gupta A, Kalaivani M, Hari P, Dinda AK, Bagga A.
Kidney Int; 2017 Jul 01; 92(1):248-257. PubMed ID: 28318625
[Abstract] [Full Text] [Related]
11. Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial.
Mathew G, Sinha A, Ahmed A, Grewal N, Khandelwal P, Hari P, Bagga A.
Pediatr Nephrol; 2022 Dec 01; 37(12):3117-3126. PubMed ID: 35286456
[Abstract] [Full Text] [Related]
12. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report.
Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A.
Clin J Am Soc Nephrol; 2010 Dec 01; 5(12):2207-12. PubMed ID: 20798255
[Abstract] [Full Text] [Related]
13. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome.
Wang J, Mao J, Chen J, Fu H, Shen H, Zhu X, Liu A, Shu Q, Du L.
Nephrology (Carlton); 2016 Jan 01; 21(1):21-7. PubMed ID: 26697959
[Abstract] [Full Text] [Related]
14. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K.
Pediatr Nephrol; 2013 Feb 01; 28(2):257-64. PubMed ID: 23052656
[Abstract] [Full Text] [Related]
15. [Long-term prognosis of patients with steroid-dependent nephrotic syndrome treated with rituximab].
Kamei K, Okada M, Miyazono A, Sato M, Fujimaru T, Ogura M, Ito S.
Nihon Jinzo Gakkai Shi; 2013 Feb 01; 55(5):947-55. PubMed ID: 23980480
[Abstract] [Full Text] [Related]
16. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus.
Sinha MD, MacLeod R, Rigby E, Clark AG.
Nephrol Dial Transplant; 2006 Jul 01; 21(7):1848-54. PubMed ID: 16311257
[Abstract] [Full Text] [Related]
17. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, Shimizu T.
Clin Exp Nephrol; 2017 Aug 01; 21(4):671-676. PubMed ID: 27558467
[Abstract] [Full Text] [Related]
18. Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children.
Larkins N, Kim S, Craig J, Hodson E.
Arch Dis Child; 2016 Apr 01; 101(4):404-8. PubMed ID: 26289063
[Abstract] [Full Text] [Related]
19. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, Oba MS, Nozu K, Iijima K.
BMC Nephrol; 2018 Nov 01; 19(1):302. PubMed ID: 30382824
[Abstract] [Full Text] [Related]
20. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
Fujinaga S, Hirano D, Nishino T, Umeda C, Watanabe Y, Nakagawa M.
Pediatr Nephrol; 2019 Nov 01; 34(11):2417-2421. PubMed ID: 31435725
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
